EVA combines AI’s speed with the rigor of scientific research to revolutionize medical development.
For decades, evidence-based medicine (EBM) has been the foundation of drug development, ensuring transparency and reproducibility. However, as scientific publications increase exponentially—with over one million new studies per year—we face a major challenge: How do we stay updated and ensure that patient care is based on the most comprehensive scientific knowledge?
EVA (Evidence in an AI age) is designed to solve this challenge.
EVA develops an AI engine that enhances evidence-based methods by continuously integrating the latest peer-reviewed research.
This ensures a more efficient, precise, and cost-effective approach to medical development.
The EVA project ensures that AI supports research rather than replacing it, accelerating innovation in life sciences, shortening the drug development timeline, and improving the detection of side effects.
This means:
- The Danish Medicines Council receives better data for their evaluations
- The life science industry can make faster, data-driven decisions
- Patients get access to better and safer treatments sooner